In a new interview with Stephen Gunnion of Proactive Investors, Custom Health CEO Shane Bishop discusses the company's Q3 2026 financial results, including 220% revenue growth to US$14.4 million, and the priorities shaping its next stage of growth.
Bishop highlights the expansion of Custom Health's pharmacy network through InnovativeRx, including organic growth following the acquisition. He also discusses the strategic value of bringing spencer® technology fully in-house, with opportunities to improve operating efficiencies and support future margin expansion.
The conversation also explores Custom Health's connected medication-management model, the importance of medication-use data, and how pharmacy services, in-home technology and clinical care work together to support patients and healthcare providers.
Read the full article on Proactive Investors.















